Gyre Therapeutics Files 8-K with Officer/Director Changes
Ticker: GYRE · Form: 8-K · Filed: Jan 6, 2025 · CIK: 1124105
| Field | Detail |
|---|---|
| Company | Gyre Therapeutics, Inc. (GYRE) |
| Form Type | 8-K |
| Filed Date | Jan 6, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, filing-update, financials
Related Tickers: GYRE
TL;DR
Gyre Therapeutics (GYRE) filed an 8-K detailing leadership changes and financial updates as of year-end 2024.
AI Summary
Gyre Therapeutics, Inc. filed an 8-K on January 6, 2025, reporting events as of December 31, 2024. The filing includes information on the departure of directors or certain officers, election of directors, appointment of certain officers, compensatory arrangements, Regulation FD disclosures, and financial statements/exhibits. The company was formerly known as Catalyst Biosciences, Inc. and Targacept Inc.
Why It Matters
This 8-K filing signals potential shifts in Gyre Therapeutics' leadership and governance, which could impact the company's strategic direction and operational focus.
Risk Assessment
Risk Level: medium — 8-K filings detailing director/officer changes and financial statements can indicate significant corporate events that may affect stock price.
Key Players & Entities
- GYRE THERAPEUTICS, INC. (company) — Registrant
- CATALYST BIOSCIENCES, INC. (company) — Former Company Name
- TARGACEPT INC (company) — Former Company Name
- Delaware (jurisdiction) — State of Incorporation
- 20250106 (date) — Filing Date
- 20241231 (date) — Period of Report
FAQ
What specific events are detailed in the 8-K filing dated January 6, 2025?
The 8-K filing details the departure of directors or certain officers, election of directors, appointment of certain officers, compensatory arrangements of certain officers, Regulation FD disclosures, and financial statements and exhibits.
What was Gyre Therapeutics, Inc. formerly known as?
Gyre Therapeutics, Inc. was formerly known as Catalyst Biosciences, Inc. and Targacept Inc.
On what date was this 8-K report filed?
This 8-K report was filed on January 6, 2025.
What is the period of report for this filing?
The conformed period of report for this filing is December 31, 2024.
Where is Gyre Therapeutics, Inc. headquartered?
Gyre Therapeutics, Inc. is headquartered at 12770 High Bluff Drive, Suite 150, San Diego, CA 92130.
Filing Stats: 1,026 words · 4 min read · ~3 pages · Grade level 9.6 · Accepted 2025-01-06 07:05:30
Filing Documents
- ef20041130_8k.htm (8-K) — 35KB
- ef20041130_ex99-1.htm (EX-99.1) — 7KB
- image0.jpg (GRAPHIC) — 40KB
- 0001140361-25-000292.txt ( ) — 236KB
- gyre-20241231.xsd (EX-101.SCH) — 4KB
- gyre-20241231_lab.xml (EX-101.LAB) — 21KB
- gyre-20241231_pre.xml (EX-101.PRE) — 16KB
- ef20041130_8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits . The following exhibits are being furnished herewith: Exhibit Number Exhibit Title or Description 99.1 Press Release, dated January 6, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GYRE THERAPEUTICS, INC. Date: January 6, 2025 By: /s/ Ruoyu Chen Name: Ruoyu Chen Title: Chief Financial Officer